Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer

• DOI: 10.1007/s10120-024-01556-9
• Publication Date: 2024-10-05T16:01:47Z
• Authors: Cecilie Riis Iden; Salah Mohammad Mu...; Nadia Øgaard; Tenna Henriksen; Sarah Østrup Jensen; Lise Barlebo Ahlborn; Kristian Egebjerg; Lene Baeksgaard; Rajendra Singh Ga...; Mette Kjølhede Ne...; Michael Patrick A...; Claus Lindbjerg A...; Morten Mau-Sørensen
• Keywords: Surgical oncology

Abstract Background Gastric and gastroesophageal junction (GEJ) cancer represents a significant global health challenge, with high recurrence rates poor survival outcomes. This study investigates circulating tumor DNA (ctDNA) as biomarker for assessing risk in patients resectable gastric GEJ adenocarcinomas (AC). Methods Patients AC, undergoing perioperative chemotherapy surgery, were prospectively enrolled. Serial plasma samples collected at baseline, after one cycle of chemotherapy, preoperative surgery. ctDNA was assessed by ddPCR test (TriMeth), which targets the gastrointestinal cancer-specific methylation patterns genes C9orf50 , KCNQ5 CLIP4 . Results analysis performed on 229 from 86 patients. At detected 56% patients, decreased to 37% following 25% 15% surgical resection. The presence associated reduced recurrence-free (RFS) (HR = 2.54, 95% confidence interval (CI) 1.33–4.85, p 0.005) overall (OS) 2.23, CI 1.07–4.62, 0.032). Similarly, surgery significantly shorter RFS 6.22, 2.39–16.2, < 0.001) OS 6.37, 2.10–19.3, 0.001). Multivariable regression confirmed an independent prognostic factor ( Conclusion has potential identify elevated recurrence, thus providing personalized treatment strategies cancer. Further validation larger cohorts ctDNA-guided interventions are needed future clinical use.